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Summary
PRINCIPLES: Most patients with arterial hypertension are
treated in primary care. The objective is to assess charac-
teristics of patients with uncontrolled arterial hypertension
and its associated determinants in Swiss primary care.
METHOD: Data on 122 adult patients with uncontrolled
hypertension (mm Hg >140 systolic and/or >90 diastolic)
was collected from the baseline data of the on-going ran-
domised controlled “CoCo” trial: Colour-coded Blood
Pressure Control. Patient and general practitioner charac-
teristics were analysed to investigate the relationship
between BP and patient characteristics.
RESULTS: From October 2009 to March 2011 30 general
practitioners recruited 122 patients; median age 64 years
(IQR 54.8–72), 50% male, median BMI 28.3 kg/m2 (IQR
25.3–31.7), 21.5% smokers. 65.6% performed home blood
pressure measurement, 88.5% received pharmacological
treatment, 41.8% mono-therapy. Most frequent dual drug
combinations: diuretics/angiotensin-receptor-blockers
(33.3%), angiotensin-converting-enzyme-inhibitors/beta
blockers (both 28.1%). BMI, smoking and age were in-
dependent predictors for elevated systolic blood pressure
when controlled for gender, home blood pressure measure-
ment, education, pulse rate and number of antihypertensive
substances. We found a significant non-linear association
between systolic blood pressure and number of antihyper-
tensive substances. Age and any amount of antihypertens-
ive substances were independently and inversely correlated
with diastolic blood pressure. The findings did not change
when additionally controlled for general practitioner clus-
tering effect.
Abbreviations
ACEI Angiotensin converting enzyme inhibitors
AH Arterial hypertension
ARB Angiotensin receptor blockers
BB Beta blocker
BP Blood pressure
CCB Calcium channel blockers
EPR Electronic patient record
GP General practitioner
HBPM Home blood pressure measurement
PC Primary care
CONCLUSION: Smoking and high BMI are strong and
independent factors associated with higher blood pressure
levels in patients with uncontrolled arterial hypertension. A
high rate of monotherapy and a decrease in the incremental
gain on blood pressure control when more antihypertensive
agents are used highlight the importance of adequate phar-
macological treatment as well as risk factor control.
Key words: arterial hypertension; blood pressure; primary
care; home blood pressure measurement; general
practitioner
Introduction
Data on patients with arterial hypertension (AH) from the
US and Europe show insufficient blood pressure (BP) con-
trol, even though effective antihypertensive treatments as
well as guideline recommendations are available [1]. Con-
sidering that AH is the most prevalent cardiovascular risk
factor worldwide [2] and that even mild AH is associated
with increased risk of cardiovascular morbidity and mortal-
ity [3, 4], it is important to emphasise the need for strict BP
control [5] and to get deeper insight into factors that hinder
its achievement.
Most of the international data on BP control originate from
national surveys, population based studies or secondary
care, despite the fact that the majority of patients are treated
in a primary care (PC) setting. Data on patients with un-
controlled AH in PC in Switzerland are limited and vary,
reporting AH control rates among patients with pharmaco-
therapy between 12.5% to 50% [6, 7]. Even the studies per-
formed in the PC setting of countries in which the general
practitioner (GP) holds a strong gate-keeping function [8,
9] are often restricted to certain ages or to already existing
antihypertensive medications. Since the gate-keeping sys-
tem in Switzerland is not generally established and is lim-
ited to certain insurance models which are currently chosen
by the minority of the population, direct knowledge trans-
fer is limited.
Therefore, the objective of this study is to investigate the
characteristics of patients with insufficiently controlled BP
in Swiss PC and to assess factors associated with uncon-
trolled BP.
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Materials and methods
Recruiting, inclusion and exclusion criteria
Data originated from baseline data of the on-going prag-
matic “CoCo”-Trial: Colour-coded Blood Pressure Control
(Trial Registration Number: NCT01013467) [10] that in-
vestigates the effect of a colour coded BP monitoring on
adherence and BP control. GPs were recruited via direct
emailing, announcing the study in a Swiss PC journal and
by information events. Patients were recruited by their par-
ticipating GP.
Inclusion criteria
– BP >140 mm Hg systolic and/or >90 mm Hg diastolic
in the practice measurement (two consecutive
measurements carried out in the practice, measured by
the GP or practice assistant at the start of the study.
Both measurements must meet the inclusion criteria
with the second measurement qualifying for
inclusion). 140 mm Hg systolic and/or 90 mmHg
diastolic was chosen as cut-off according to current
Swiss guidelines for the treatment of AH [11]
– No change in AH medication within the last month
– Patient able to perform self-monitoring
– Written informed consent
Exclusion criteria
– Insufficient knowledge of the German language for
instruction and BP recording with a booklet
– BP above 180 mm Hg systolic and/or 110 mm Hg
diastolic (due to safety/risk considerations)
– Serious general or psychological illness (malignant
tumours, serious depressive episodes or evidence of
dementia)
GPs asked all consecutively appearing patients with known
AH and fitting inclusion criteria for consent to participate
in the study. Also patients without known diagnoses of AH
who underwent routine BP measurement at the practice
where asked for consent to participate in the study if the
practice measurement was >140 mm Hg systolic or >90
mm Hg diastolic and no exclusion criteria existed. The in-
clusion and exclusion criteria were low threshold in order
to reflect real life situation. Inclusion began in October
2009 and ended in March 2011.
Blood pressure measurement
In accordance with guidelines [12, 13] two consecutive os-
cillometric BP readings were performed in seated position
after a resting period of at least 5 minutes. The physicians
all used the same validated BP measuring devices (Mio-
Star Cardioplus 500) which were provided by the Insti-
tute of General Practice and Health Services Research. GPs
were instructed to choose appropriate cuffs according to the
upper-arm circumference of the patients.
Socio-demographic and clinical information
Additional socio-demographic and clinical information
(age, weight, height, smoking habits, years of education
[starting in primary school], previous home-BP-measure-
ment [HBPM]) were collected. Antihypertensive medica-
tion was classified as follows: Angiotensin receptor block-
ers (ARB), Calcium channel blockers (CCB), Beta-block-
ers (BB), Angiotensin converting enzyme inhibitors
(ACEI), diuretics and other antihypertensive drugs.
Data processing
The anonymous data forms were faxed to the project lead-
ers and data was entered by an independent employee. All
patients gave written informed consent.
The study protocol was approved by the ethics committee
of Zurich (Kantonale Ethikkommission (KEK) Zürich
(EK-1738).
Statistical analysis
Continuous variables were tested for normal distribution by
the Shapiro-Wilk test and presented accordingly as medi-
an and interquartile range (IQR) or as mean and standard
deviation (SD), categorical data are presented as frequen-
cies. We compared patient and GP characteristics using
non parametric (wilcoxon rank sum) and parametric (un-
paired t-test) tests, depending on normal distribution tests.
Univariate linear regression analyses were performed to
investigate the relationship between systolic and diastolic
BP and all available patient characteristics. To investigate
the independent association between BP measures and pa-
tient characteristics, multiple linear regression was applied.
For the multiple linear regression models the same patient
characteristics were considered as for the univariate ana-
lyses, irrespective of the significance levels based on the
univariate analysis. The possibility of a non-linear relation-
ship between BP measurements and the number of anti-
hypertensive agents was taken into account by introducing
a quadratic term of the predictor variable into the model.
The purpose of introducing the quadratic term was to in-
vestigate the possibility of diminishing efficacy of multiple
combination therapy on BP control. Goodness of fit (R2)
was compared between models (i.e. linear- and non-linear
modelling) by F-tests. We further used multilevel regres-
sion analysis with the GP as cluster level thus taking in-
to account that patient observations are not independent,
i.e. observations in one cluster tend to be more similar to
each other than to individuals in the rest of the sample. The
amount of clustering (i.e., the variation that is explained by
the GP level) was assessed by calculating the intraclass cor-
relation coefficient (ICC) ranging from 0% (i.e., no evid-
ence for clustering) to 100% (i.e., all the variation in BP
difference is explained on GP level). A two-sided alpha of
0.05 was set as level of significance for all comparisons.
All analyses were calculated using the STATA statistical
package, version 11.2 (Stata Incorporation, College Sta-
tion, TX, USA).
Results
Between end of October 2009 and March 2011, 122 pa-
tients were included in the study.
Patient characteristics
Data on 122 adult patients with uncontrolled AH (above
140 mm Hg systolic and/or 90 mm Hg diastolic) [11] was
collected. In table 1 the detailed study population char-
acteristics can be appreciated. 43.8% of the patients were
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overweight (BMI between 25 and 30 kg/m2), 34.7% were
obese (BMI 30 kg/m2 and more), median BMI was 28.3
kg/m2 (IQR 25.3–31.7). Slightly greater than half (52.1%)
of patients were persistent (21.5%) or ex-smokers (30.6%).
The mean systolic and diastolic BP was 157 and 92 mm
Hg (SD 15.3 and 9.7). The majority performed HBPM at
the time of inclusion into the study (65.6%). 60.0% of pa-
tients met inclusion criteria for both systolic and diastol-
ic BP, 36.7% only for systolic and 3.3% only for diastolic
BP. Data on patients receiving and not receiving pharmaco-
logical AH treatment were pooled for all further analyses
since at the time of inclusion into the study besides diastol-
ic BP no difference in patient characteristics (e.g., HBPM,
gender, age, BMI, education pulse rate, smoking status and
systolic BP) existed.
Medication
88.5% of the patients received antihypertensive treatment,
in 41.8% a mono-therapy, followed by a dual therapy
(30.3%). 16.4% received three or more antihypertensive
agents. In total, 46.7% of patients with uncontrolled AH re-
ceived 2 or more antihypertensive agents (fig. 1).
Figure 1
Distribution of number of antihypertensive agents per patient. Total
population n = 122. The majority of patients received a
monotherapy.
Figure 2
Overall distribution of antihypertensive agents. Other refers to
imidazolin receptor antagonist (= moxonidin; causes blood pressure
lowering by central adrenergic stimuli with resulting reduction in
peripheral vascular resistance). ACEI and diuretics were the overall
most commonly prescribed antihypertensive substances.
BB = beta blockers; CCB = calcium channel blockers; ARB =
angiotensin receptor blockers; ACEI = angiotensin converting
enzyme inhibitors.
The overall most commonly prescribed antihypertensive
agents were ACEI (44.6%), followed by diuretics (42.6%)
and ARB (34.7%), BB (30.7%) and CCB (16.8 %) (fig. 2).
ACEI were the most commonly prescribed monotherapy
(39.2%), followed by ARB (29.4%), BB (17.7%), diuretics
(9.8%) and CCB (6.9%).
The most established dual drug combinations were diuretic
+ ARB (33.3%), followed by diuretic + ACEI, as well as
diuretic + BB (both 28.1%) (fig. 3).
Influence of patient characteristics on blood pressure
The univariate regression analyses of patient characteristics
influencing systolic and diastolic BP are presented in table
2. Smoking status (former and current compared to never
smokers) was significantly and positively associated with
systolic BP, whereas BMI only showed a trend for positive
association (p = 0.071). The number of antihypertensive
agents showed no linear relationship with systolic BP.
However, taking into account a non-linear association (i.e.,
including a quadratic term) revealed a significant associ-
ation between systolic BP and number of antihypertensive
agents. Amount of antihypertensive agents (linear as well
as non-linear term) and age were significantly associated
with lower diastolic BP, whereas BMI and pulse rate were
positively associated with diastolic BP.
The multivariate analyses for patient characteristics influ-
encing systolic and diastolic BP are presented in table 3.
Smoking status (current compared to never smokers), BMI
and age were independently and positively associated with
higher systolic BP. There was a significant and independent
negative association between systolic BP and number of
antihypertensive agents. The non-linear (quadratic) term
of the number of AH agents was significantly and posit-
ively associated with systolic BP, suggesting a decrease of
the incremental efficacy of additional antihypertensive sub-
stances in lowering systolic BP. Age and the number of
Figure 3
Distribution of antihypertensive dual drug combinations.
Composition of dual combination therapies used in the study
population (n = 57 with 2 or more antihypertensive drugs). Other
refers to imidazolin receptor antagonist. The most commonly
prescribed dual drug combination was diuretics with angiotensin
receptor blockers.
D = diuretics; BB = beta blockers; CCB = calcium channel blockers;
ARB = angiotensin receptor blockers; ACEI = angiotensin
converting enzyme inhibitors.
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antihypertensive substances were independently and negat-
ively associated with diastolic BP. Goodness of fit for the
multivariate model (R2) was significantly increased when a
non-linear association between systolic BP and number of
BP medications was taken into account, resulting in R2 val-
ues of 21.6% (linear model) and 30.0% (non-linear model),
respectively (p = 0.01 for comparison). For diastolic BP the
non-linear model did not result in an increased goodness of
fit in the multivariate model. Corresponding R2 values for
linear and non-linear model were 31.7% and 33.7% (p =
0.10 for comparison). The main findings of the multivari-
ate analyses concerning independent associations between
patient characteristics and BP were not changed when addi-
tionally controlled for the GP as potential cluster effect: In
a multilevel regression analysis no clustering effect of GPs
on systolic (ICC = 0.04%, p = 0.998) and diastolic (ICC =
10.50%, p = 0.237) BP could be found. The mean number
of patients included by GPs in to the study was 4.06 (range
1–8).
GP characteristics
30 GPs from three German speaking cantons, mainly urban
(n = 10) and suburban (n = 13) areas of Switzerland (rural n
= 7) participated in the study. Significantly more GPs were
male (73.3% vs 26.7 %, p <0.05). Thirteen GPs worked
in single handed and 17 in group practices. They were all
either specialised in internal (n = 15) or general medicine
(n = 15). The female participants were significantly young-
er (median 50 vs 58.5 years, IQR 40–51 vs 48–62, p <0.05)
and worked a significantly shorter period of time in the
practice (median 2 vs 26, IQR 1–17 vs 3–27, p <0.05), even
though the time since completion of the board examina-
tion was comparable between the genders (overall mean 28
years). Male and female GPs worked mainly full time, fe-
male GPs were more likely to use electronic patient records
(EPR) (71.4% vs 23.8%, p <0.05). EPRs have been imple-
mented in practice routine, on average, for 3.5 years (IQR
1–6 years).
Discussion
Our study in patients with uncontrolled AH in Swiss PC
showed that in this real life setting about 40% of patients
were under single pharmacological treatment. We further
found a non-linear (quadratic) relationship between the
number of antihypertensive agents and systolic BP. Age,
overweight and smoking resulted as predominant factors
associated with the level of systolic BP in patients having
insufficient BP control.
Table 1: Patient characteristics.
Age (years) 64 (54.8–72.0)
Male (%) 50
BMI (kg/m2)
Normal (BMI 18.5–25 kg/m2), (%)
Overweight (BMI 25–30 kg/m2), (%)
Obese (BMI >30 kg/m2), (%)
28.3 (25.3–31.7)
21.5
43.8
34.7
Smoking status (%)
Never smoked
Stopped smoking
Still smoking
47.9
30.6
21.5
Education (years) 10.0 (8.25–14.0)
Previous home BP-measurement (%) 65.6
Antihypertensive treatment (%) 82.8
Systolic BP (mm Hg) 157.3 (15.3)
Diastolic BP (mm Hg) 91.9 (9.7)
Pulse rate (per minute) 75.0 (11.1)
Continuous variables are presented as median (IQR) or mean (SD).
Table 2: Patient characteristics and univariate influence on systolic and diastolic blood pressure.
Univariate analysis systolic BP Univariate analysis diastolic BPCharacteristics
Regression
coefficient
95% CI Regression
coefficient
95% CI
Home-BP-measurement (ref = no) 0.54 –5.83 to 6.92 –2.13 –6.12 to 1.86
Gender (ref = male) –2.98 –8.89 to 2.92 –1.14 –4.88 to 2.58
Linear
Number of antihypertensive agents
0.53 –2.53 to 3.59 –3.51 –5.36 to –1.67*
Nonlinear
Number of antihypertensive agents linear term
Quadratic Term Number of antihypertensive agents
–12.48
4.10
–22.56 to –2.39*
1.06 to 7.14*
–9.43
1.86
–15.57 to –3.28*
0.01 to 3.71*
Age (years) 0.13 –0.10 to 0.36 –0.33 –0.46 to –0.20*
BMI (kg/m2) 0.55 –0.05 to 1.15 0.45 0.08 to 0.82*
Education (years) –0.57 –1.26 to 0.13 –0.21 –0.65 to 0.22
Ex-smoker (ref = non-smoker) 8.62 1.93 to 15.30* –0.81 –5.20 to 3.57
Current smoker (ref = non-smoker) 9.46 2.24 to 16.67* 1.79 –2.95 to 6.53
Pulse rate (counts/min) –0.12 –0.38 to 0.13 0.16 0.00 to 0.31*
*p <0.05
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Factors influencing systolic and
diastolic BP
Although with these data and study design we cannot pos-
tulate a causal relation, a relation between BMI and
smoking and insufficient BP control is to be presumed. In
the literature elevated BMI and older age are known factors
associated with high systolic BP [4, 14–16] and weight re-
duction has shown to significantly reduce systolic BP [17].
Our data are in line with these findings, where BMI and
age were independent positive predictors for systolic BP
when controlled for gender, HBPM, treatment and educa-
tion. The observed inverse correlation between diastolic BP
and age is a known phenomenon explained by the dimin-
ished elastic capacity of the large arteries with increasing
age, leading to reduced distension during the systole and
consequently lower diastolic BP [15, 18–20].
In our study smoking seemed to have the most significant
effect on systolic BP with one third of the patients being
former smokers and a fifth still active smokers. We did not
find an association between diastolic BP and smoking, a
finding which is in congruence with other epidemiological
data in the literature [21]. However, interventional and epi-
demiological data on the effect of smoking cessation on BP
have shown conflicting results [22].
Our conclusions on factors influencing BP control drawn
from a study population only consisting of patients with un-
controlled AH seem justified when considering the results
of a recent Swiss study also including patients with con-
trolled AH (<140/90 mm Hg) [23]; there the BP control
rate was higher in non-smokers and in patients with a BMI
<25 kg/m2.
Home blood pressure measurement and medication
In our study population most patients performed HBPM
before inclusion into the study and diastolic BP was lin-
early negatively associated with the amount of antihyper-
tensive substances, suggesting good adherence with ther-
apy.
It is known, that the efficacy of antihypertensive treatment
proven in clinical trials is not always reflected in the real
life of clinical practice [24]. Reasons for insufficient BP
control are diverse, lack of adherence and insufficient self-
monitoring have been shown to play an important role on
the patients’ side [25–29], reluctance to intensify therapy
can be a reason in patients and physicians [24]. In ad-
dition, among GPs uncertainness and scepticism whether
guideline recommendations are always adequate for the in-
dividual patient exist [30].
Guidelines promote an early dual combination treatment
[11, 12]. We observed a gap between this guideline recom-
mendation and practice, since about half of the patients
under pharmacological treatment and uncontrolled AH re-
ceived only a monotherapy.
Overall, the most commonly prescribed antihypertensive
agents were ACEI followed by diuretics and ARB, BB
and CCB. As stated in Guidelines for the Management of
AH [11, 12], randomised trials comparing antihypertensive
substances show that for similar BP reductions, differences
in the incidence of cardiovascular morbidity and mortal-
ity between different drug classes are small, thus strength-
ening the conclusion that their benefit largely depends on
BP lowering per se. Depending on co-morbidities, there
is evidence in favour of certain drug classes versus others
either as initial treatment or as part of a combination. Also
side effects may influence the choice of therapy. Since co-
morbidities and side effects were not recorded in our data,
no statement can be made concerning the guideline con-
formity with respect to the chosen substances, particularly
the high use of beta-blockers as monotherapy.
Our adjusted results estimated an average decrease in
systolic BP due to an antihypertensive monotherapy com-
pared to no treatment of 10.66 mm Hg (i.e. –15.58 mm
Hg of the linear term plus 4.92 mm Hg of the quadratic
term) and an average diastolic decrease of 6.46 mm Hg (i.e.
–7.97 mm Hg plus 1.51 mm Hg) (table 3). These effects are
comparable to randomised trials comparing antihypertens-
ive agents with placebo [31].
We observed a non-linear (quadratic) association between
BP measures and number of antihypertensive substances
which was stronger for systolic BP. These findings reflect
the diminishing efficacy of multiple combination therapy
on BP control; the incremental effect of an antihypertensive
monotherapy declines with every additional substance, a
conclusion also recently drawn by Justin et al. [32].
Multimorbidity and polypharmacy is a common problem in
PC associated with increased risk of interactions and side
effects. In this setting “more is not always better” [33].
Therefore the important goal of good BP control has to
consider not only the most adequate and evidence based
Table 3: Patient characteristics and multivariate influence on systolic and diastolic blood pressure.
Multivariate analysis systolic BP Multivariate analysis diastolic BPCharacteristics
Regression
coefficient
95% CI Regression
coefficient
95% CI
Home-BP-measurement (ref = no) –0.37 –6.67 to 5.92 2.58 –1.2 to 6.44
Gender (ref = male) –2.56 –8.19 to 3.06 –1.62 –5.07 to 1.83
Number of antihypertensive agents –15.58 –25.48 to –5.68* –7.97 –14.04 to –1.90*
Quadratic term
Number of antihypertensive agents
4.92 1.98 to 7.86* 1.51 –0.29 to 3.32
Age (years) 0.37 0.13 to 0.61* –0.25 –0.40 to –0.10*
BMI (kg/m2) 0.78 0.18 to 1.38* 0.11 –0.25 to 0.47
Education (years) –0.41 –1.06 to 0.24 –0.30 –0.70 to 0.10
Ex-smoker (ref = non-smoker) 6.03 –0.52 to 12.58 –2.27 –6.28 to 1.75
Current smoker (ref = non-smoker) 13.17 6.10 to 20.19* –0.82 –5.12 to 3.47
Pulse rate (counts/min) –0.09 –0.33 to 0.15 0.08 –0.07 to 0.22
*p <0.05
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treatment but also has to reflect the benefits and risks. In
addition, as shown in our study and mentioned above, oth-
er factors for insufficient BP control as overweight and
smoking are frequent concomitant problems. Multifaceted
interventions, including modification of lifestyle, with
smoking cessation and weight reduction, should be raised
implicitly and offered to patients, especially to the ones
already receiving a dual antihypertensive combination ther-
apy. From the management of other chronic diseases in PC,
such as diabetes, it is known that interventions with the
greatest positive effect on outcomes include support in be-
haviour change [30, 34–37].
Strengths and limitations
Certain limitations concerning the generalisability of our
data have to be taken into account: Previous studies from
the PC setting have shown that variations between GPs oc-
cur [38–40], meaning that patient observations are not in-
dependent, i.e. observations in one cluster tend to be more
similar to each other than to individuals in the rest of the
sample. In our study population no such expected cluster
effect was observed, meaning that the variations in patient
observations are not explained by the attending GP. This
finding might indicate that our GP population represents a
special selection. Even though we could not find a GP clus-
tering effect on BP, such effects cannot always be ruled out
with certainty. Participating GPs differed from Swiss GP
population statistics, performed by the Swiss Medical As-
sociation [41], in the following points: More than half of
the participating GPs worked in group practices, whereas
usually this is the case in one third of Swiss GPs. The num-
ber of GPs with electronic patient records was also higher
than average, with 36% compared to the reported data of
13% in Switzerland [42, 43]. Only GPs from three cantons
of the German speaking part of Switzerland were recruited
for participation and most participants were located in urb-
an or suburban areas. For Swiss standards, the participat-
ing GPs treated a proportionally large amount of patients in
managed care or HMO systems [44]. On the other hand the
gender and age distribution compared well with the annu-
al statistics on GPs [41]. The participating physicians also
reflected the traditional characteristics of a Swiss GP, spe-
cialising in internal or general medicine without additional
specialisation.
Each participating GP received along with the study folder
a list and instructions to register all patients they asked to
participate and all patients who declined to participate.
However, this list was not completed by the majority of
GPs and therefore could not be considered for analysis. No
patients were excluded by the study investigators. The GPs
were responsible for making sure that the inclusion and ex-
clusion criteria were met, hence, correct inclusion and ex-
clusion has to be trusted. Nevertheless, the low-threshold
inclusion criteria were strengths because they offered a
view on real life PC patients with AH and on the spec-
trum of treatment. On the other hand, certain clinical de-
tails which could influence the reason for uncontrolled AH,
e.g., renal function, hyperaldosteronism, effect of BP-influ-
encing medications such as NSAR are lacking. Since the
current manuscript concentrates on the baseline-measure-
ments only performed at the practices white coat hyper-
tension in some cases cannot be excluded. Nevertheless, it
seems justified to rely on the presumption that GPs know
about white coat hypertension and took this consideration
into account before including the patient into the study.
From our study data no statements on the prevalence of un-
controlled AH in Swiss PC can be derived. But considering
the existing data on high prevalence of (uncontrolled) AH
in Switzerland [6, 7] and worldwide [1], our findings are of
importance.
Conclusions
Smoking and high BMI are strong and independent factors
associated with higher BP levels in patients with uncon-
trolled AH. A high rate of monotherapy and a decrease
in the incremental gain on BP control when more anti-
hypertensive agents are used highlight the importance of
adequate pharmacological treatment as well as risk factor
control.
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Figures (large format)
Figure 1
Distribution of number of antihypertensive agents per patient. Total population n = 122. The majority of patients received a monotherapy.
Figure 2
Overall distribution of antihypertensive agents. Other refers to imidazolin receptor antagonist (= moxonidin; causes blood pressure lowering by
central adrenergic stimuli with resulting reduction in peripheral vascular resistance). ACEI and diuretics were the overall most commonly
prescribed antihypertensive substances.
BB = beta blockers; CCB = calcium channel blockers; ARB = angiotensin receptor blockers; ACEI = angiotensin converting enzyme inhibitors.
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Figure 3
Distribution of antihypertensive dual drug combinations. Composition of dual combination therapies used in the study population (n = 57 with 2
or more antihypertensi drugs). Other refers to imidazolin receptor antagonist. The most commonly prescribed dual drug combination was
diuretics with angiotensin receptor blockers.
D = diuretics; BB = beta blockers; CCB = calcium channel blockers; ARB = angiotensin receptor blockers; ACEI = angiotensin converting
enzyme inhibitors.
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